• Respiratorius posted no net sales in Q2 2026, while loss after financial items narrowed to SEK 1.78 million from SEK 1.81 million.
• Earnings per share improved to SEK -0.23 from SEK -0.35, while equity ratio rose to 99.01% from 96.12% a year earlier.
• For H1 2026, loss after financial items narrowed to SEK 3.51 million from SEK 3.81 million, while EPS improved to SEK -0.44 from SEK -0.75.
• Management said multiple partnering meetings led counterparties to evaluate VAL001, while the company will present at Nordic Star 2026 Pitch Competition in September.
• Funding is expected to cover operations through February 2027, with the company continuing to run a cost-conscious, efficient resource plan.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Respiratorius AB published the original content used to generate this news brief via Cision (Ref. ID: 202608110231BITN____UKPR__SV_20260810-BIT-6106-0) on August 11, 2026, and is solely responsible for the information contained therein.